Inogen Inc (INGN) EVP Matt Scribner Sells 2,500 Shares
Inogen Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $116.17, for a total value of $290,425.00. Following the completion of the sale, the executive vice president now directly owns 7,297 shares of the company’s stock, valued at $847,692.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Matt Scribner also recently made the following trade(s):
- On Thursday, December 14th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $120.34, for a total value of $300,850.00.
- On Monday, November 13th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $112.35, for a total value of $280,875.00.
Inogen Inc (INGN) opened at $118.12 on Friday. The company has a market capitalization of $2,399.88, a price-to-earnings ratio of 96.03, a P/E/G ratio of 3.90 and a beta of 1.13. Inogen Inc has a 12-month low of $62.69 and a 12-month high of $130.05.
Hedge funds have recently modified their holdings of the stock. Simplex Trading LLC bought a new position in Inogen in the fourth quarter worth $153,000. Schroder Investment Management Group bought a new position in Inogen in the second quarter worth $132,000. Ameritas Investment Partners Inc. raised its stake in Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 86 shares in the last quarter. Victory Capital Management Inc. raised its stake in Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after acquiring an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. raised its stake in Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 33 shares in the last quarter.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Leerink Swann reaffirmed an “outperform” rating and issued a $120.00 target price (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Needham & Company LLC raised their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $102.71.
COPYRIGHT VIOLATION NOTICE: “Inogen Inc (INGN) EVP Matt Scribner Sells 2,500 Shares” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/20/inogen-inc-ingn-evp-matt-scribner-sells-2500-shares.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.